Pharmacokinetics and drug interactions - Relevant factors for the choice of a drug

International Journal of Clinical Pharmacology and Therapeutics

Volumn 34, Issue SUPPL. 1, 1996, Pages

  Zech, K ^a   Steinijans, V W ^a   Huber, R ^a   Kolassa, N ^a   Radtke, H W ^a  

^a ALTANA PHARMA AG   (Germany)

Author keywords

Clearance; Drug interaction; Lansoprazole; Omeprazole; Pantoprazole; Pharmacokinetics; Proton pump inhibitor

Indexed keywords

ALCOHOL; BISMUTH; CAFFEINE; CARBAMAZEPINE; CONTRACEPTIVE AGENT; CYCLOSPORIN; DEBRISOQUINE; DIAZEPAM; DICLOFENAC; DIGOXIN; GLIBENCLAMIDE; LANSOPRAZOLE; LIDOCAINE; MEPHENYTOIN; METHOTREXATE; METOPROLOL; NIFEDIPINE; OMEPRAZOLE; PANTOPRAZOLE; PHENAZONE; PHENPROCOUMON; PHENYTOIN; PROPRANOLOL; PROTON PUMP INHIBITOR; QUINIDINE; THEOPHYLLINE; WARFARIN;

ARTICLE; DRUG ABSORPTION; DRUG CHOICE; DRUG DEVELOPMENT; DRUG DISPOSITION; DRUG DOSE; DRUG ELIMINATION; DRUG FORMULATION; HUMAN; REPRODUCIBILITY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANIMALS; BENZIMIDAZOLES; DRUG INTERACTIONS; ENZYME INHIBITORS; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; OMEPRAZOLE; SULFOXIDES;

EID: 0029896612     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Ahmad S 1991 Omeprazole-warfarin interaction. South Med J 84: 674-675
2. Andersson T, Andren K, Cederberg C, Edvardsson G, Heggelund A, Lundborg P 1990a Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol 39: 51-54
3. Andersson T, Cederberg C, Regårdh CG, Skånberg I 1990b Pharmacokinetics of various single intravenous and oral doses of omeprazole. Eur J Clin Pharmacol 39: 195-197
4. Andersson T, Andrén K, Cederberg C, Lagerstrom PO, Lundborg P, Skånberg I 1990c Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol 29: 557-563
5. Andersson T, Cederberg C, Heggelund A, Lundborg P 1991 The pharmacokinetics of single and repeated once-daily doses of 10, 20 and 40 mg omeprazole as enteric-coated granules. Drug Invest 3: 45-52
6. Andersson T 1991 Omeprazole Drug Interaction Studies. Clin Pharmacokinet 21: 195-212
7. Benet LZ, Zech K 1994 Pharmacokinetics -a relevant factor for the choice of a drug. Aliment Pharmacol Ther 8 (Suppl.1): 25-32
8. Bergendal L, Friberg A, Schaffrath A 1995 Potential drug-drug interactions in 5,125 mostly elderly out-patients in Gothenburg, Sweden. Pharm World Sci 17: 152-157
9. Bergstrand R, Grind M, Nyberg G, Olofsson B 1995 Decreased oral bioavailability of lansoprazole in healthy volunteers when given with a standardised breakfast. Clin Drug Invest 9: 67-71
10. +-ATPase inhibitor pantoprazole after single intravenous administration. Int J Clin Pharmacol Ther 32: 44-50
11. Colin-Jones DG 1993 Safety of lansoprazole. Aliment Pharmacol Ther 7 (Suppl. 1): 56-60
12. Delhotal-Landes B, Cournot A, Vermerie N, Dellatolas F, Benoit M, Flouvat B 1991 The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet 16: 315-320
13. Delhotal-Landes B, Petite JP, Flouvat B 1995 Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 28: 458-470
14. Fitton A, Wiseman L 1996 Pantoprazole - a review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 51: 460-482
15. Fuchs W, Sennewald R, Klotz U 1994 Lansoprazole does not affect the bioavailability of oral contraceptives. Br J Clin Pharmacol 38: 376-380
16. García B, Lacambra C, Garrote F, García-Plaza I, Solis J 1994 Possible potentiation of anticoagulant effect of acenocoumarol by omeprazole. Pharm World Sci 16: 231-232
17. Granneman GR, Karol MD, Locke CS, Cavanaugh JH 1995 Pharmacokinetic interaction between lansoprazole and theophylline. Ther Drug Monit 17: 460-464
18. Gugler R, Jensen JC 1985 Omeprazole inhibits oxidative drug metabolism. Gastroenterol 89: 1235-1241
19. Gugler R, Jensen JC 1987 Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. Pharmacol Ther 33: 133-137
20. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E 1995 Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 9: 363-378
21. Huber R, Hartmann M, Bliesath H, Lühmann R, Steinijans VW, Zech K 1996 Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 34:185-194
22. Hussein Z, Grannemann GR, Mukherjee D, Samara E, Hogan DL, Koss MA, Isenberg JI 1993 Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol 36: 391-398
23. Jansen JBMJ, Lundborg P, Baak LC, Greve J, Ohman M, Stöver C, Röhss K, Lamers CBHW 1988 Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man. Gut 29: 75-80
24. Kokufu T, Ihara N, Sugioka N, Koyama H, Ohta T, Mori S, Nakajima K 1995 Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol 48: 391-395
25. Naidu MUR, Shobha JC, Dixit VK, Kumar A, Kumar TR, Sekhar EC 1994 Effect of multiple dose omeprazole on the pharmacokinetics of carbamazepine. Drug Invest 7: 8-12
26. Pearce RE, Rodrigues AD, Goldstein J, Parkinson NN 1995 Identification of the human P450 enzymes involved in lansoprazole metabolism. Abstract booklet, p. 6, First International Symposium on Drug Drug Interactions: scientific and regulatory perspectives, Nov. 13.-14. 1995, St. Louis, MO, USA
27. Petersen KU 1995 Review article: omeprazole and the cytochrome P450 system. Aliment Pharmacol Ther 9: 1-9
28. Prichard PJ, Walt KP, Kitchingman GK, Somerville KW, Langman MJS, Williams J, Richens A 1987 Oral phenytoin pharmacokinetics during omepraole therapy. Br J Clin Pharmacol 24: 543-545
29. Roux A, Naline E, Molinier P, Dellatolas F, Lemaire M, Flouvat B 1993 Effect of lansoprazole and omeprazole on the metabolism of theophylline and antipyrine in man. Eur J Drug Metab Pharmacokin 18: 125
30. Shader RI 1993 I recently saw a patient taking omeprazole for a duodenal ulcer who was wobbly and sedated by the small doses of diazepam that he had previously tolerated. How is this explained? J Clin Psychopharmacol 13: 459
31. Steinijans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, Radtke HW 1996 Lack of pantoprazole drug interactions in man: un updated review. Int J Clin Pharmacol Ther 34 (Suppl. 1): S31-S50
32. Sutfin T, Balmer K, Boström H, Eriksson S, Höglund P, Pauken O 1989 Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 11: 176-184